TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8173702

Group type: EXPERIMENTAL
Intervention: Diltiazem (180-360 mg daily)
Number of subjects: 12000

Group type: COMPARATOR
Intervention: Conventional treatment (diuretics or beta-adrenergic blockers)
Number of subjects: 12000
Study: 3507006

Group type: EXPERIMENTAL
Intervention: Beef extended with soy isolate, soy concentrate, or soy flour (20% reconstituted soy product, 80% beef)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Beef extended with soy products fortified with 60 mg Fe and 25 mg Zn/100 g protein
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control group consuming their usual self-selected diet
Number of subjects: 52
Study: 31830761

Group type: EXPERIMENTAL
Intervention: Overweight mothers
Number of subjects: 935

Group type: COMPARATOR
Intervention: R-BMI mothers
Number of subjects: 935
Study: 29534403

Group type: EXPERIMENTAL
Intervention: Regular dosage of fasudil (30 mg)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Large dosage of fasudil (60 mg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Comparison between large dosage and regular dosage groups
Number of subjects: 60
Study: 26603174

Group type: EXPERIMENTAL
Intervention: Artesunate-mefloquine (target dose 12 mg/kg artesunate and 25 mg/kg mefloquine)
Number of subjects: 252

Group type: COMPARATOR
Intervention: Chloroquine (target dose 25 mg/kg)
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: Artesunate-mefloquine
Number of subjects: 252

Group type: COMPARATOR
Intervention: Chloroquine
Number of subjects: 252
Study: 24684390

Group type: EXPERIMENTAL
Intervention: ketamine
Number of subjects: 22

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 22
Study: 22594097

Group type: EXPERIMENTAL
Intervention: Cinnamon oil and pogostemon oil complex
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Cinnamon oil
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Pogostemon oil
Number of subjects: 60
Study: 21199118

Group type: EXPERIMENTAL
Intervention: Short-handled Macintosh laryngoscope
Number of subjects: 40

Group type: COMPARATOR
Intervention: Pediatric Bullard laryngoscope
Number of subjects: 40
Study: 16962170

Group type: EXPERIMENTAL
Intervention: Regular aspirin users
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Regular acetaminophen users
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Greater frequency of acetaminophen use (>7 tablets weekly)
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Greater duration of acetaminophen use (>10 years)
Number of subjects: 600
Study: 16260979

Group type: EXPERIMENTAL
Intervention: 6.4% carbohydrate‐electrolyte solution (CHO)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Water placebo (PLA)
Number of subjects: 9
Study: 12079632

Group type: EXPERIMENTAL
Intervention: Botulinum toxin type B (BTX‐B) at 1000 units (conversion of 50 units of BTX‐B to 1 unit of BTX‐A)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Botulinum toxin type B (BTX‐B) at 2000 units (conversion of 100 units of BTX‐B to 1 unit of BTX‐A)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Botulinum toxin type A (BTX‐A) at 20 units
Number of subjects: 0
Study: 10467790

Group type: EXPERIMENTAL
Intervention: Reformulated 2-rod Norplant implant
Number of subjects: 11
Study: 7604806

Group type: EXPERIMENTAL
Intervention: Fluvastatin at 20 mg twice daily
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Gemfibrozil at 600 mg twice daily
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Combination of fluvastatin and gemfibrozil
Number of subjects: 17
Study: 2123072

Group type: EXPERIMENTAL
Intervention: Recombinant tissue-type plasminogen activator (rt-PA) administered within 4 hours from symptom onset (group A)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Recombinant tissue-type plasminogen activator (rt-PA) administered between 4 and 8 hours from symptom onset (group B)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional therapy (group C)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Recombinant tissue-type plasminogen activator (rt-PA) (group A)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Recombinant tissue-type plasminogen activator (rt-PA) (group B)
Number of subjects: 60
Study: 360249

Group type: EXPERIMENTAL
Intervention: Carbamazepine (300-600 mg daily for six weeks)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo tablets
Number of subjects: 10
Study: 31324444

Group type: EXPERIMENTAL
Intervention: Thymoglobulin induction with tacrolimus and/or mycophenolate mofetil maintenance, steroids not used beyond 1 week
Number of subjects: 186
Study: 28168363

Group type: EXPERIMENTAL
Intervention: Induction of labor at 38 weeks
Number of subjects: 100

Group type: COMPARATOR
Intervention: Induction of labor at 40 weeks
Number of subjects: 100
Study: 24698092

Group type: EXPERIMENTAL
Intervention: Cue‐induced alcohol craving measured with visual analogue scales at 60 days of abstinence.
Number of subjects: 319

Group type: EXPERIMENTAL
Intervention: Cue‐induced alcohol craving measured with visual analogue scales at 7, 14, and 30 days of abstinence.
Number of subjects: 319

Group type: EXPERIMENTAL
Intervention: Heart rate, blood pressure, and skin conductance responses at 7, 14, 30, and 60 days of abstinence.
Number of subjects: 319
Study: 23175622

Group type: EXPERIMENTAL
Intervention: Imatinib mesylate (IM) interruption and rechallenge
Number of subjects: 71
Study: 21757321

Group type: EXPERIMENTAL
Intervention: Trunk Control Measurement Scale (TCMS)
Number of subjects: 26
Study: 19086714

Group type: EXPERIMENTAL
Intervention: Transanal irrigation for 10 weeks
Number of subjects: 62
Study: 16116596

Group type: EXPERIMENTAL
Intervention: GnRH agonist treatment
Number of subjects: 65
Study: 12384828

Group type: EXPERIMENTAL
Intervention: Lifestyle modification program including intensive lifestyle management and frequent telephone counseling.
Number of subjects: 2205

Group type: COMPARATOR
Intervention: Conventional therapy (CON)
Number of subjects: 2205
Study: 10419922

Group type: EXPERIMENTAL
Intervention: Methotrexate 7.5 mg/wk
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 8543521

Group type: EXPERIMENTAL
Intervention: Primary diagnosis of major depression, anxiety, disruptive disorders, substance use
Number of subjects: 236

Group type: EXPERIMENTAL
Intervention: Primary dysthymia
Number of subjects: 236

Group type: EXPERIMENTAL
Intervention: Age of onset of disorder
Number of subjects: 236

Group type: EXPERIMENTAL
Intervention: Remission intervals between episodes (well time)
Number of subjects: 236
Study: 2186776

Group type: EXPERIMENTAL
Intervention: Papaverine 100 mg q.d.s. orally for 4 weeks
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 6157256

Group type: EXPERIMENTAL
Intervention: Low-dose heparin
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Dextran 70
Number of subjects: 168

Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 168
Study: 31002954

Group type: EXPERIMENTAL
Intervention: 18F-FDG PET/CT
Number of subjects: 540

Group type: COMPARATOR
Intervention: Conventional imaging
Number of subjects: 540
Study: 28162984

Group type: EXPERIMENTAL
Intervention: Eltrombopag (50 mg to 300 mg)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 25359121

Group type: EXPERIMENTAL
Intervention: Self-rating of the effects of alcohol (SRE) questionnaire
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Presence of relationship breakups
Number of subjects: 163
Study: 23537982

Group type: EXPERIMENTAL
Intervention: Routine early percutaneous coronary intervention (r-PCI)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard approach of performing early PCI only for failed fibrinolysis (s-PCI)
Number of subjects: 0
Study: 21709064

Group type: EXPERIMENTAL
Intervention: Intracoronary adeno‐associated virus type 1/sarcoplasmic reticulum Ca(2+)‐ATPase
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study: 19455177

Group type: EXPERIMENTAL
Intervention: Cholecalciferol 120,000 U in fifth and seventh gestational months (Group C)
Number of subjects: 139

Group type: COMPARATOR
Intervention: Cholecalciferol 60,000 U in fifth month of gestation (Group B)
Number of subjects: 139

Group type: COMPARATOR
Intervention: No cholecalciferol (Group A)
Number of subjects: 139
Study: 16704893

Group type: EXPERIMENTAL
Intervention: Screening arm (PSA testing)
Number of subjects: 4278

Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 4278
Study: 16278621

Group type: EXPERIMENTAL
Intervention: Group education and an educational booklet on the first day of therapy, counseling in the third and sixth months
Number of subjects: 119

Group type: COMPARATOR
Intervention: No counseling or education
Number of subjects: 119
Study: 12036860

Group type: COMPARATOR
Intervention: Gemtuzumab ozogamicin (GO) without IL-11
Number of subjects: 51

Group type: COMPARATOR
Intervention: Gemtuzumab ozogamicin (GO) with IL-11
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Idarubicin plus continuous-infusion, high-dose cytosine arabinoside (IA)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Gemtuzumab ozogamicin (GO) with or without IL-11
Number of subjects: 51
Study: 10550850

Group type: EXPERIMENTAL
Intervention: Propofol 6% SAZN
Number of subjects: 0

Group type: COMPARATOR
Intervention: Propofol 1% SAZN
Number of subjects: 0

Group type: COMPARATOR
Intervention: Diprivan‐10
Number of subjects: 0
Study: 7832595

Group type: EXPERIMENTAL
Intervention: Micronutrient antioxidants (alpha‐tocopherol and beta‐carotene)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ongoing randomized trials of primary and secondary prevention
Number of subjects: 0
Study: 2126652

Group type: EXPERIMENTAL
Intervention: Short-term occlusive dressing (24h)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Prolonged occlusion (5-28 days)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Optimal prolonged occlusion dressing
Number of subjects: 36
Study: 7000222

Group type: EXPERIMENTAL
Intervention: Cyproterone acetate (300 mg intramuscularly per week)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Oestradiol undecylate (100 mg intramuscularly per month)
Number of subjects: 42
Study: 31340598

Group type: EXPERIMENTAL
Intervention: NoTrap! program (experimental group)
Number of subjects: 622

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 622
Study: 28135221

Group type: EXPERIMENTAL
Intervention: Partial-body cryotherapy (PBC) for 150 seconds at -130 to -160° C
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control group in a thermo neutral room (22.0 ± 0.5° C)
Number of subjects: 200
Study: 26319124

Group type: EXPERIMENTAL
Intervention: Endoscopic technique
Number of subjects: 41

Group type: COMPARATOR
Intervention: Open technique
Number of subjects: 41
Study: 23799886

Group type: EXPERIMENTAL
Intervention: e-CUIDATE (telerehabilitation with exercise planning including breathing exercises, mobility, strength, and stretching)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care (control group maintaining their usual routine)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: e-CUIDATE
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 22551481

Group type: EXPERIMENTAL
Intervention: BNP: peripheral nerve blockage with 80mg of lidocaine, 100mg of mepivacaine and 25mg of levobupivacaine
Number of subjects: 111

Group type: COMPARATOR
Intervention: INF: surgical wound infiltration with 50mg of levobupivacaine
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: BNP
Number of subjects: 111

Group type: COMPARATOR
Intervention: INF
Number of subjects: 111
Study: 19337061

Group type: EXPERIMENTAL
Intervention: Educational programme 'to live with the sun' taught by teachers
Number of subjects: 282

Group type: COMPARATOR
Intervention: Control group (B) with no educational programme
Number of subjects: 282
Study: 17533053

Group type: EXPERIMENTAL
Intervention: Fucoidan ingestion (galactofucan sulfate)
Number of subjects: 0
Study: 15159645

Group type: EXPERIMENTAL
Intervention: Resource Mother group (RM group)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 50
Study: 11917446

Group type: EXPERIMENTAL
Intervention: Lidocaine jelly at 2%
Number of subjects: 90

Group type: COMPARATOR
Intervention: Chlorexidine gluconate
Number of subjects: 90
Study: 9722227

Group type: EXPERIMENTAL
Intervention: Intranasal fluticasone propionate 0.1 mg o.d. (n=26)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Intranasal fluticasone propionate 0.2 mg o.d. (n=25)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo (n=12)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Controls (n=6)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Patients (n=44)
Number of subjects: 63
Study: 8036306

Group type: EXPERIMENTAL
Intervention: Inhaled budesonide
Number of subjects: 216

Group type: COMPARATOR
Intervention: Control (no inhaled steroids)
Number of subjects: 216
Study: 2730826

Group type: EXPERIMENTAL
Intervention: Undiluted i.m. preparation (25 mg ml‐1)
Number of subjects: 149

Group type: COMPARATOR
Intervention: Diluted i.m. preparation in normal saline (5 mg ml‐1)
Number of subjects: 149
Study: 30996379

Group type: EXPERIMENTAL
Intervention: Potassium nitrate
Number of subjects: 150

Group type: COMPARATOR
Intervention: Stannous fluoride
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study: 30078892

Group type: EXPERIMENTAL
Intervention: Decompression with fusion
Number of subjects: 139

Group type: COMPARATOR
Intervention: Decompression alone
Number of subjects: 139
Study: 27770150

Group type: EXPERIMENTAL
Intervention: Single-step mandibular advancement group (SSG)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Stepwise mandibular advancement group (SWG)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 51
Study: 24450365

Group type: EXPERIMENTAL
Intervention: 90 N mobilization
Number of subjects: 64

Group type: COMPARATOR
Intervention: 30 N mobilization
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo (detuned laser)
Number of subjects: 64
Study: 22183215

Group type: EXPERIMENTAL
Intervention: Laparoscopic hysterectomy
Number of subjects: 59

Group type: COMPARATOR
Intervention: Abdominal hysterectomy
Number of subjects: 59
Study: 20379194

Group type: EXPERIMENTAL
Intervention: Interval training
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Continuous exercise training
Number of subjects: 65

Group type: COMPARATOR
Intervention: Control (sedentary routine)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Continuous and interval exercise training
Number of subjects: 65
Study: 17647115

Group type: EXPERIMENTAL
Intervention: Heidelberg Retina Tomograph II (HRT) parameters
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Standard automated perimetry (SAP)
Number of subjects: 450

Group type: COMPARATOR
Intervention: Ocular hypertensive group
Number of subjects: 450
Study: 16091396

Group type: EXPERIMENTAL
Intervention: Infliximab (5 mg/kg/6 weeks)
Number of subjects: 20
Study: 11943439

Group type: EXPERIMENTAL
Intervention: Donepezil
Number of subjects: 104

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 104
Study: 10676476

Group type: EXPERIMENTAL
Intervention: Selenium concentration in serum (55 +/- 11 micrograms Se/L)
Number of subjects: 470

Group type: EXPERIMENTAL
Intervention: Selenium concentration in hair (0.268 +/- 0.040 microgram Se/g)
Number of subjects: 470

Group type: EXPERIMENTAL
Intervention: Selenium concentration in urine (12 +/- 5 micrograms Se/L)
Number of subjects: 470
Study: 7573869

Group type: EXPERIMENTAL
Intervention: Different end-tidal carbon dioxide and volatile agent concentrations during maintenance of anaesthesia
Number of subjects: 60
Study: 2147813

Group type: EXPERIMENTAL
Intervention: Verapamil 360 mg/day
Number of subjects: 1785

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1785

Group type: EXPERIMENTAL
Intervention: Verapamil (combined results from meta-analysis)
Number of subjects: 1785
Study: 7452472

Group type: EXPERIMENTAL
Intervention: Magnesium salicylate
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Choline magnesium trisalicylate
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 18
Study: 29756749

Group type: EXPERIMENTAL
Intervention: Flurbiprofen oral spray
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Benzydamine hydrochloride oral spray
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo spray
Number of subjects: 150
Study: 30420364

Group type: EXPERIMENTAL
Intervention: OMSC+ (OMSC plus performance coaching)
Number of subjects: 166

Group type: COMPARATOR
Intervention: OMSC (control group)
Number of subjects: 166
Study: 27115264

Group type: EXPERIMENTAL
Intervention: Quality improvement intervention including daily checklist and goal setting during multidisciplinary rounds with follow‐up clinician prompting for 11 care processes
Number of subjects: 6761

Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 6761

Group type: EXPERIMENTAL
Intervention: Quality improvement intervention
Number of subjects: 6761
Study: 25214161

Group type: EXPERIMENTAL
Intervention: Nutritional education and supplemental iron administration (iron polymaltose complex)
Number of subjects: 310

Group type: COMPARATOR
Intervention: Standard information on prevention of IDA (Control group)
Number of subjects: 310

Group type: EXPERIMENTAL
Intervention: Iron medication for >6 months
Number of subjects: 310

Group type: EXPERIMENTAL
Intervention: Breastfeeding for >6 months
Number of subjects: 310
Study: 23110608

Group type: EXPERIMENTAL
Intervention: Inpatient Brief Psychodynamic Psychotherapy
Number of subjects: 130

Group type: COMPARATOR
Intervention: Treatment-as-usual
Number of subjects: 130
Study: 21190574

Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy (CBT)
Number of subjects: 330

Group type: COMPARATOR
Intervention: Supportive therapy (ST)
Number of subjects: 330
Study: 17285386

Group type: EXPERIMENTAL
Intervention: Dexamethasone 8 mg after induction of anesthesia
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Metoclopramide 10 mg just before the end of anesthesia
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Dexamethasone 8 mg after induction of anesthesia and Metoclopramide 10 mg before the end of anesthesia
Number of subjects: 160

Group type: COMPARATOR
Intervention: 0.9% NaCl (placebo)
Number of subjects: 160
Study: 16583989

Group type: EXPERIMENTAL
Intervention: Standard Antibiotic Therapy (SAT) combined with amikacin
Number of subjects: 152

Group type: COMPARATOR
Intervention: Other Antibiotic Therapy (OAT) combined with amikacin
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Amikacin used in high once daily dose (HODD) with SAT or OAT
Number of subjects: 152

Group type: COMPARATOR
Intervention: Conventional Therapy (CT)
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Amikacin HODD with TDM
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Amikacin HODD without TDM
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Direct costs of treatment with SAT
Number of subjects: 152

Group type: COMPARATOR
Intervention: Direct costs of treatment with OAT
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Hospitalization costs per patient
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Cost reduction by omitting TDM in patients without risk factors
Number of subjects: 152

Group type: EXPERIMENTAL
Intervention: Overall cost reduction by introducing safe and cheap standard treatment
Number of subjects: 152
Study: 11966929

Group type: EXPERIMENTAL
Intervention: Enamel matrix proteins (EMD) applied in test subjects
Number of subjects: 166

Group type: COMPARATOR
Intervention: Control group without EMD
Number of subjects: 166
Study: 10712814

Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA) 500 mg
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 8818069

Group type: EXPERIMENTAL
Intervention: School-based intervention
Number of subjects: 1182

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1182

Group type: EXPERIMENTAL
Intervention: School-only and school-plus-family intervention groups
Number of subjects: 1182
Study: 1600043

Group type: EXPERIMENTAL
Intervention: Micronutrient antioxidant therapy (600 micrograms organic selenium, 9000 i.u. beta-carotene, 0.54 g vitamin C, 270 i.u. vitamin E, 2 g methionine)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Micronutrient antioxidant therapy
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 3901731

Group type: EXPERIMENTAL
Intervention: Bismuth subsalicylate liquid
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo liquid
Number of subjects: 29
Study: 30871594

Group type: EXPERIMENTAL
Intervention: Bosentan 62.5 mg twice daily for 28 ± 2 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bosentan
Number of subjects: 0
Study: 30643068

Group type: EXPERIMENTAL
Intervention: Fluvoxamine combined with extended-release methylphenidate (MPH-ER)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Fluvoxamine and placebo
Number of subjects: 44
Study: 27789196

Group type: EXPERIMENTAL
Intervention: Local consolidative therapy (chemo/radiotherapy or resection of all lesions)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Maintenance treatment alone (could be observation)
Number of subjects: 74
Study: 24745634

Group type: EXPERIMENTAL
Intervention: Low health literacy
Number of subjects: 844

Group type: COMPARATOR
Intervention: Adequate health literacy
Number of subjects: 844
Study: 22722530

Group type: EXPERIMENTAL
Intervention: Depot medroxyprogesterone acetate (DMPA) 150 mg intramuscularly every 12 weeks for 24 weeks
Number of subjects: 84

Group type: COMPARATOR
Intervention: Continuous oral contraceptive (OC) pills (ethinyl estradiol 0.03 mg and gestodene 0.075 mg) daily for 24 weeks
Number of subjects: 84
Study: 20421832

Group type: EXPERIMENTAL
Intervention: 12-month moderate-intensity physical activity (PA) intervention
Number of subjects: 424

Group type: COMPARATOR
Intervention: Successful aging health education intervention
Number of subjects: 424
Study: 18034919

Group type: EXPERIMENTAL
Intervention: Erythropoiesis-stimulating agents (ESA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Epoetin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Darbepoetin alpha
Number of subjects: 0
Study: 15878183

Group type: EXPERIMENTAL
Intervention: ADHD group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 0
Study: 14516212

Group type: EXPERIMENTAL
Intervention: Attended source (A or B)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nonattended source
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Signal detection theory application
Number of subjects: 0